RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.320
+0.005 (0.38%)
At close: Aug 20, 2026, 4:00 PM EDT
1.330
+0.010 (0.76%)
After-hours: Aug 20, 2026, 5:41 PM EDT
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
The company was founded in 2009 and is headquartered in Mountain View, California.
RenovoRx, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Aug 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Shaun Bagai |
Contact Details
Address: 2570 West El Camino Real, Suite 320 Mountain View, California 94040 United States | |
| Phone | 650 284 4433 |
| Website | renovorx.com |
Stock Details
| Ticker Symbol | RNXT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 1574094 |
| CUSIP Number | 75989R107 |
| ISIN Number | US75989R1077 |
| Employer ID | 27-1448452 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shaun R. Bagai | Chief Executive Officer, Secretary and Director |
| Dr. Ramtin Agah M.D. | Founder, Executive Chairman and Chief Medical Officer |
| Ronald B. Kocak CPA, CGMA | Vice President of Finance and Controller |
| Mark Voll | Chief Financial Officer and Principal Accounting Officer |
| Robert Strasser | Vice President of Operations and Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K/A | [Amend] Current report |
| Aug 12, 2026 | 8-K | Current Report |
| Aug 4, 2026 | 8-K | Current Report |
| Jul 2, 2026 | 8-K | Current Report |
| Jun 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 30, 2026 | 8-K | Current Report |
| May 15, 2026 | 10-K/A | [Amend] Annual report |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |